Noxxon Pharma AG
Noxxon Pharma is a therapeutic drug development company founded in 1999 and located in Berlin, Germany, that focuses on development of drugs based off of Spiegelmer Technology. Noxxon has aggressively pursued patents on Spiegelmers, so that they alone can exclusively exploit this market. They have several drugs in various phases of clinical trials targeting a variety of diseases.
Larry Gold is the founder, CEO, and chairman of the board of SomaLogic. Located in Boulder, Colorado, and founded in 1999, SomaLogic develops aptamer-based technology and markets diagnostic agents.
SomaLogic has its own aptamer-based technology called SOMAmer™, which bind to proteins, and SOMAscan™, which are diagnostic assays.
Both technologies focus on measuring thousands of proteins to
Innovators: The Companies
Click logos to visit company websites.
Text Citation 54: Noxxon employee pipetting.
Text Citation 54
Text Citation 54: Noxxon employee pipetting.
SomaLogic's SOMAmer - Slow Off-rate Modified Aptamer
SomaLogic's SOMAmer - Slow Off-rate Modified Aptamer
choose "the right target, the right compound, and the right patients" to streamline product development for other companies. This "accelerates successful drug discovery and development across the pipeline, from preclinical target discovery to post-market surveillance and companion diagnostics."
They market this technology as SOMAscan™ that identifies these protein biomarkers as the "right target."
Gilead Sciences, Inc.
"Advancing Therapeutics. Improving Lives."
Gilead Sciences was founded in 1987 in Foster City, California. Gilead
absorbed NeXstar Pharmaceuticals, Inc., the company that Larry Gold originally founded using the patents that he had recently been awarded for the SELEX technology.
Gilead thus had rights to the SELEX process and was responsible for licensing these rights to other companies such as Archemix and Noxxon Pharma. These patents have since expired.
Gilead has a variety of therapeutic drugs for sale, including treatments for HIV/AIDS, Liver Disease, Cardiovascular/Metabolic, Respiratory, and others. Gilead is a marketing partner for Macugen.
"Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need."
Gilead markets 15 products.
SOMAscan
SOMAscan
(i) - SOMAmers attached to streptavidin beads bind to proteins in the sample mix
(ii) - proteins that are bound to SOMAmers are then biotinylated
(iii) - The SOMAmer-protein complexes are released by photocleaving the linker, and non-specific SOMAmer-protein complexes are separated (center pair)
(iv) - Biotinylated proteins are bound to a second streptavidin bead
(v) - Bound SOMAmers are removed from their protein targets
(vi) - SOMAmers are collected and denatured
(vii) - SOMAmers are measured using standard DNA analysis techniques like microarrays.
Page Contents
• Aptagen
• SomaLogic
• Noxxon Pharma AG
• Gilead Sciences, Inc.
• AptSci, Inc.
• AptaMatrix
• Base Pair Biotechnologies
• NeoVentures Biotechnology, Inc.
• AMBiotech
"Unlocking protein biomarkers to transform healthcare"
SomaLogic
SAAAAptagen
"Advancing Aptamer Applications"
Aptagen was founded in 2004 and is located in Jacobus, Pennsylvania, and provides a variety of aptamer-based services. Aptagen custom-generates all three types of aptamers for research, diagnostics, and therapeutics.
From their website, one can use their easy-to-use AptaBuilder (TM) to purchase custom-created aptamers (see below).
Aptagen also offers several aptamers for a variety of applications (see the Aptagen flyer linked below).
Aptamer Sciences Inc.
"Aptamer Solutions for the
Biopharmaceutical Industry"
AptSci Inc. was founded in 2011 and is based in Pohang, South Korea. AptSci's focus is on "commercializing cutting-edge technologies for analysis of proteins, based on its...aptamer technology platforms."
AptSci offers over 200 aptamers, which "can be provided within 2~4 weeks at cost."
AptaMatrix
"To accelerate the discovery of aptamers and be
the leading provider of aptamer based sensing technologies."
AptaMatrix was founded in 2003 and is located in Syracuse, New York. The company developed the High Throughput Screening of Aptamers (HTSA) process as an alternative to SELEX, and is patent pending. AptaMatrix also developed AlloSwitch™ technology, which are aptamer-based bio-sensors that "transduce molecular recognition into an optical signal in near-real time" - basically functioning as instantaneous sensors.
Base Pair Biotechnology, Inc.
"The Aptamer Discovery Company"
Base Pair Biotechnology, Inc., has been active since 2004 and is located in Houston, Texas.
This company offers a variety of services, from "standard" development of custom aptamers to other therapeutics-related development and diagnostic assays. There are about 40 aptamers in their catalog. Base Pair also specializes in aptamer research funded by grants, working alongside government agencies such as the Environmental Protection Agency, the National Institute of Health, the National Cancer Institute, the National Institute of Environmental Health Sciences, and the National Science Foundation.
Base Pair has also worked with a substantial number of esteemed institutions on top of the others listed, including the Centers for Disease Control, the M.D. Anderson Cancer Center, the United States Air Force, Stanford University, several colleges in the University of California system (San Francisco, Davis, Berkeley), the Universities of Toronto, Houston, Washington, and Bath, CSIR South Africa, Technische Universität Dresden (TUD), Universitat Rovira i Virgili (URV), University di Parma, Italy, and the Johns Hopkins University among others.
NeoVentures Biotechnology, Inc.
NeoVentures was founded in 2002, and is located in London, Canada. They focus on diagnostic agents, and market several aptamer-based diagnostic assays that target toxins in wine, corn, bear, and wheat.
AMBiotech
AMBiotech was founded in 2006 and is located in Houston Texas. The company is built around their Microbead Aptamer Selection Process which produces Thioaptamers, which are based on phosphorodithioate (PS2) DNA. This technology simultaneously selects the DNA sequence and chemical modifications for the Thioaptamer.
AMBiotech offers its services in both standard oligonucleotide synthesis or custom Thioaptamers, which can be used in both diagnostics and therapeutics.
